Deficiency in the Treatment Description of mTOR Inhibitor Resistance in Medulloblastoma, a Systematic Review

Medulloblastoma drugs in development: Current leads, trials and drawbacks

(2021) Jiachen Wen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Overview and recent advances in the targeting of medulloblastoma cancer stem cells

(2021) Megan Rose Paul et al.   Expert Review of Anticancer Therapy

MiR-592 activates the mTOR kinase, ERK1/ERK2 kinase signaling and imparts neuronal differentiation signature characteristic of Group 4 medulloblastoma

(2021) Raikamal Paul et al.   HUMAN MOLECULAR GENETICS

The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications

(2021) Patrick Y Wen et al.   NEURO-ONCOLOGY

mTOR signaling at the crossroads of environmental signals and T‐cell fate decisions

(2020) Hongling Huang et al.   IMMUNOLOGICAL REVIEWS

A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma

(2020) Nagendra K Chaturvedi et al.   MOLECULAR CANCER THERAPEUTICS

A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology

(2020) Julia Lorenz et al.   Acta Neuropathologica Communications

The role of Shh signalling pathway in central nervous system development and related diseases

(2020) Xiaoying Li et al.   CELL BIOCHEMISTRY AND FUNCTION

Research progress of mTOR inhibitors

(2020) Yifan Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Medulloblastoma

(2019) Paul A. Northcott et al.   Nature Reviews Disease Primers

mTOR Is Key to T Cell Transdifferentiation

(2019) Jiawei Yan et al.   Cell Metabolism

Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells

(2019) Francesca Charini et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

mTOR: Role in cancer, metastasis and drug resistance

(2019) Avaniyapuram Kannan Murugan   SEMINARS IN CANCER BIOLOGY

Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma

(2019) Frank Eckerdt et al.   Scientific Reports

A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors

(2019) Muna Qayed et al.   PEDIATRIC BLOOD & CANCER

Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

(2018) Hideki Makinoshima et al.   CANCER RESEARCH

Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations

(2018) Ye-Lim Park et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting mTOR as a Therapeutic Approach in Medulloblastoma

(2018) Juncal Aldaregia et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Role of mTOR Complexes in Neurogenesis

(2018) Francesca LiCausi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells

(2018) Ella Lineham et al.   Oncotarget

Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy

(2018) Nagendra K. Chaturvedi et al.   Oncotarget

The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy

(2018) Lilla Hornyák et al.   Frontiers in Immunology

World Health Organization 2016 Classification of Central Nervous System Tumors

(2018) Phedias Diamandis et al.   NEUROLOGIC CLINICS

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

(2017) N. Basset-Séguin et al.   EUROPEAN JOURNAL OF CANCER

Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer

(2017) Lu Zhang et al.   JNCI-Journal of the National Cancer Institute

A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma

(2017) Dan R Laks et al.   NEURO-ONCOLOGY

BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma

(2017) Ping Zhao et al.   PLoS One

Challenges and Recent Advances in Medulloblastoma Therapy

(2017) Vinod Kumar et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer

(2017) Lu Zhang et al.   JNCI-Journal of the National Cancer Institute

Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group

(2016) Tomoyuki Mizuno et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma

(2016) Yanxin Pei et al.   CANCER CELL

MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma

(2016) Shaofang Wu et al.   MOLECULAR CANCER THERAPEUTICS

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

(2016) Vanessa S. Rodrik-Outmezguine et al.   NATURE

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors

(2016) Oren J. Becher et al.   PEDIATRIC BLOOD & CANCER

BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells

(2016) Kan He et al.   Oncotarget

IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma

(2016) Valentina Folgiero et al.   Oncotarget

Toward rapamycin analog (rapalog)-based precision cancer therapy

(2015) Ling-hua Meng et al.   ACTA PHARMACOLOGICA SINICA

RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors

(2015) X. Zhao et al.   CANCER RESEARCH

Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma

(2015) V. Dimitrova et al.   CURRENT MOLECULAR MEDICINE

Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment

(2015) Kazuhiro Tanaka et al.   JOURNAL OF CLINICAL INVESTIGATION

Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells

(2015) Frank Eckerdt et al.   Oncotarget

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors

(2015) Burhan Hassan et al.   Oncotarget

Rapamycin: One Drug, Many Effects

(2014) Jing Li et al.   Cell Metabolism

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

(2014) Min H. Kang et al.   PEDIATRIC BLOOD & CANCER

Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma

(2013) Matija Snuderl et al.   CELL

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma

(2013) Mary Rose Pambid et al.   PEDIATRIC BLOOD & CANCER

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study

(2013) Rochelle Bagatell et al.   PEDIATRIC BLOOD & CANCER

Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study

(2012) Hajime Asahina et al.   INVESTIGATIONAL NEW DRUGS

Novel mutations target distinct subgroups of medulloblastoma

(2012) Giles Robinson et al.   NATURE

Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program

(2012) C. Patrick Reynolds et al.   PEDIATRIC BLOOD & CANCER

Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors

(2011) Sheri L. Spunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of Tsc1 In Vivo Impairs Hippocampal mGluR-LTD and Increases Excitatory Synaptic Function

(2011) H. S. Bateup et al.   JOURNAL OF NEUROSCIENCE

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

(2011) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER

Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

(2010) S. Buonamici et al.   Science Translational Medicine

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist

(2010) Shifeng Pan et al.   ACS Medicinal Chemistry Letters

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

Perifosine: Update on a novel Akt inhibitor

(2009) Joell J. Gills et al.   Current Oncology Reports

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE